Anshul Mangal is CEO of Project Farma (PF) and President of PerkinElmer OneSource. A biotech entrepreneur and attorney, Anshul founded PF and scaled it into a global consultancy specializing in advancing manufacturing and technical operations for complex biologics and novel therapies. Under his leadership, PF pioneered the industrialization of groundbreaking therapeutics, including the first-ever commercially approved cell and gene, radioligand, and RNA-based therapies, and cutting-edge biologics. Additionally, Anshul led M&A for PF, bolstering its ability to offer comprehensive solutions to drug developers facing manufacturing challenges. PF’s achievements include leading 100+ facility builds with a total capital investment exceeding $6BB, managing 400+ capital projects, and collaborating with 100+ life science companies. Anshul’s commitment to advancing next-generation medicines extends past PF to various boards and philanthropic organizations, including IQHQ, Alliance for Regenerative Medicines, Alliance for mRNA Medicines, Institute for Life Changing Medicines and several patient-advocacy organizations.
The cell and gene therapy sector has hit incredible milestones in recent years. As the sector continues to evolve and the climate becomes increasingly crowded and volatile, leaders must remain flexible in constantly refining the pipeline.